Ann: BCT expansion order from Global Pharma client and Update, page-3

Agree. Both the Chairman and CEO jumped the gun with their enthusiasm in last years' annual report and the Fuji deal died at that point.

These comments from the 2023 annual report certainly have aged terribly and to the detriment of all shareholders...


One can only hope that Cogent Venture Partners can generate competitive tension in the process they are running to claw back some value for shareholders. With a current market cap of $6m one would think that a decently run, competitive process can extract some value materially above this figure (particularly as there is also $3m of inventories that would be included in any deal struck).